8 completed, 6 active not recruiting, 5 recruiting, 1 terminated. 12 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3.
Follow Adenocarcinoma, Clear Cell: new trials by email Literature Review of Adenocarcinoma, Clear Cell trials Research Report on Adenocarcinoma, Clear Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-01 | 2026-09-16 |
| Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma Lymphodepleting chemotherapy, Dexamethasone, Fludarabine - Clear Cell Carcinoma, Phase 1 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-09-25 | 2026-04-29 |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | North Eastern German Society of Gynaecological Oncology | 640 | 2024-10-11 | 2026-10-23 |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Oncological Follow-up - Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor | Phase 2 | Recruiting | Centre Oscar Lambret | 88 | 2024-02-28 | 2026-03-18 |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Dostarlimab, Bevacizumab, Doxorubicin - Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | Active not recruiting | Yonsei University | 198 | 2024-01-22 | 2026-11-02 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers KFA115, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2022-10-26 | 2026-10-20 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. Image-guided adjuvant pelvic radiotherapy - Endometrioid Adenocarcinoma, Serous Carcinoma | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 23 | 2020-08-26 | 2025-08-01 |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Rucaparib, Placebos - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | North Eastern German Society of Gynaecological Oncology | 42 | 2020-06-08 | 2024-11-15 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy 13C-Glucose, 13C-Acetate, 13C-Lactate - Kidney Cancer, Renal Cell Carcinoma | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 600 | 2019-09-30 | 2026-01-28 |
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Nivolumab, Ipilimumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Active not recruiting | Brown University | 46 | 2018-04-30 | 2026-08-20 |
| A Study of Nivolumab in Selected Uterine Cancer Patients Nivolumab - Uterine Cancer, Endometrial Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 35 | 2017-08-03 | 2024-12-27 |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Sunitinib - Ovarian Cancer, Adverse Effects | Phase 2 | Completed | Cathay General Hospital | 30 | 2013-01-01 | 2018-07-18 |
| Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Endometrioid Carcinoma, Clear Cell Carcinoma | Withdrawn | University Hospital, Basel, Switzerland | 2012-10-01 | 2015-04-01 | ||
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas alemtuzumab, fludarabine, sirolimus - Ewing Sarcoma, Gastrointestinal Tumor | Phase 1 | Completed | St. Jude Children's Research Hospital | 23 | 2012-08-20 | 2026-02-06 |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma 124IcG250 - Renal Cancer | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2012-04-01 | 2026-07-08 |
| Ovarian Clear Cell Adenocarcinoma Review Ovarian Cysts | Completed | Cathay General Hospital | 5 | 2008-04-01 | 2019-08-09 | |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Erlotinib, Carboplatin, Paclitaxel - Non-Small Cell Lung Cancer, Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 68 | 2007-11-01 | 2019-11-20 |
| High-dose Bevacizumab in Advanced Renal Carcinoma Patients Bevacizumab - Renal Cancer, Kidney Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 119 | 2007-02-01 | 2014-12-22 |
Showing 20 of 22. Sign in to see all of them.
Ovarian Neoplasms (10) · Fallopian Tube Neoplasms (5) · Kidney Neoplasms (4) · Carcinoma, Renal Cell (3) · Carcinosarcoma (3) · Endometrial Neoplasms (3) · Carcinoma, Endometrioid (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Melanoma (2) · Uterine Cervical Neoplasms (2) · Uterine Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Mucinous (1)
Neoplasms by Histologic Type (22) · Neoplasms, Glandular and Epithelial (22) · Adenocarcinoma (21) · Carcinoma (21) · Neoplasms (21) · Neoplasms by Site (19) · Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Urogenital Diseases (18) · Urogenital Neoplasms (18) · Genital Diseases (14) · Genital Diseases, Female (14) · Genital Neoplasms, Female (14) · Adnexal Diseases (12) · Endocrine System Diseases (12)
Bevacizumab (3) · Paclitaxel (3) · Carboplatin (2) · Gemcitabine (2) · Nivolumab (2) · fludarabine (2) · pembrolizumab (2) · Alemtuzumab (1) · Busulfan (1) · Capecitabine (1) · Celecoxib (1) · Dexamethasone (1) · Disulfides (1) · Docetaxel (1) · Doxorubicin (1)
Cathay General Hospital (2) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · North Eastern German Society of Gynaecological Oncology (2) · Brown University (1) · Centre Oscar Lambret (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mark H. Einstein (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Rambam Health Care Campus (1) · SCRI Development Innovations, LLC (1) · St. Jude Children's Research Hospital (1) · Tufts Medical Center (1) · University Hospital, Basel, Switzerland (1)
United States (13) · Germany (3) · Japan (3) · South Korea (3) · Taiwan (3) · Canada (2) · France (2) · Hong Kong (2) · Italy (2) · Singapore (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1) · China (1)
Andrew C Johns, MD (1) · Brando Triplett, MD (1) · Chih-Ming Ho (1) · Chih-Ming Ho, Ph.D. (1) · Claire Friedman, MD (1) · Darren Feldman, MD (1) · David D'Souza, M.D. (1) · Don Dizon, MD (1) · Eliahu Gez, MD (1) · Ellen C Obermann, MD (1) · Ellen Obermann, MD, Dr. (1) · Jalid Sehouli, Prof. Dr. (1) · Jalid Sehouli, Prof. Dr. med. (1) · John D. Hainsworth, M.D. (1)
PMID 25968826, PMID 28438473, PMID 31722153, PMID 37185961, PMID 38653864, PMID 39710508, PMID 39990653, PMID 40382284, PMID 42140839
F31CA239330 (1), P50CA196516 (1), R35CA220449 (1), U10CA027469 (1), U10CA180868 (1)